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put millions of patients in a better place,
too.
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Phosphoinositide-3-OH kinases (PI3K) are critical regulators of cell metabolism, growth, and survival. In a re-
cent publication in Nature, Jia et al. (2008) identify specific functions of the p110b isoform of PI3K in glucose
metabolism, cellular proliferation, and tumorigenesis.Class IA PI3Ks are members of a con-
served family of lipid kinases comprised
of a p85 regulatory subunit and a p110 cat-
alytic subunit. There are two ubiquitously
expressed class IA catalytic isoforms,
p110a and p110b. Class IA PI3Ks are acti-
vated by receptor tyrosine kinases (RTKs).
The p110b catalytic subunit can also be
activated through G protein-coupled re-
ceptors (GPCRs) (Hazeki et al., 1998). Ac-
tivation of PI3K results in the conversion of
PI(4,5)P2 to PIP3; the latter binds to pleck-
strin homology (PH) domains of various
signaling proteins, including the serine/
threonine kinase Akt. Dysregulation of
PI3K signaling is implicated in the patho-
genesis of diabetes mellitus and cancer
(Engelman et al., 2006). The p110a iso-
form of PI3K has been the most exten-
sively studied to date, and the gene en-
coding this enzyme is frequently mutated
in human cancers. However, in a recent
issue of Nature, Jia et al. (2008) identify
unique roles for p110b in cellular metabo-
lism and oncogenesis.In the liver, p110a appears to be the
predominant PI3K isoform activated fol-
lowing insulin receptor stimulation (Fou-
kas et al., 2006). Indeed, Jia et al. (2008)
show that deletion of p110b does not af-
fect the ability of insulin to activate Akt in
the liver, which supports the results of
prior pharmacologic studies showing
that p110b does not play a significant
role in insulin-stimulated Akt activation
(Knight et al., 2006). However, Jia et al.
(2008) found that the absence of p110b
impairs insulin repression of gluconeo-
genic genes and leads to glucose intoler-
ance. Many insulin-repressed genes in
the liver contain binding sites for FOXO
transcription factors, and expression of
constitutively active FOXO leads to in-
creased gluconeogenic gene expression
(Zhang et al., 2006). Notably, mice hetero-
zygous for both p110a and p110b exhibit
glucose intolerance despite intact insulin-
stimulated AKT activity, suggesting that
factors in addition to Akt are required for
insulin signaling in the liver (BrachmannCell Metabolism 8,et al., 2005). Jia et al. (2008) did not exam-
ine FOXO phosphorylation, and other ki-
nases, in addition to Akt, can phosphory-
late FOXO. However, FOXO is one of
many transcription factors contributing
to PEPCK expression; therefore, full re-
pression in the presence of insulin may re-
quire activation of an as-yet-unidentified
signaling complex by p110b and may
occur in a PIP3-independent manner (see
Figure 1A). Alternatively, p110b catalytic
activity and PIP3 production might be re-
quired for repression of PEPCK by insulin.
It is known that pharmacologic inhibition
of p110b does not block acute Akt phos-
phorylation, but it does significantly inhibit
PIP3 generation. This observation raises
the possibility that while p110a activation
alone produces more than sufficient PIP3
for acute AKT activation, additional PIP3-
dependent responses that require higher
levels of this lipid or that require PIP3 pro-
duction at a unique location by p110b play
additional roles in suppression of gluco-
neogenesis.September 3, 2008 ª2008 Elsevier Inc. 179
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(A) Under conditions where PTEN is present, Akt is activated predominantly by the RTK-p110a pathway,
as occurs in the liver after insulin stimulation. Insulin-induced activation of Akt results in the phosphoryla-
tion of FOXO transcription factors and ultimately, the inhibtion of target gene expression. However, p110b
is required for full repression of glucoeneogenic gene expression (e.g., the PEPCK gene) by insulin, sug-
gesting that this isoform activates downstream kinases in addition to Akt and/or regulates transcription
factors in addition to FOXO. The specific activation of non-Akt kinases by p110b may require either the
generation of spacially restricted pools of PIP3 within the cell or the generation of quantities of PIP3
exceeding those required for Akt activation.
(B) Under conditions where PTEN expression is reduced, as occurs in many human tumors, the basal level
of PIP3 is increased due to unopposed p110b activity. These increased basal levels of PIP3 result in
increased Akt activity and increased cell growth. In both scenarios (A and B) p110b may also function
in a PIP3-independent manner such that its catalytic activity is not required for regulation of downstream
signaling. In this model, p110b serves as a ‘‘molecular scaffold’’ for recruiting additional catalytically active
signaling molecules. See text for further details.180 Cell Metabolism 8, September 3, 2008 ª2008 Elsevier Inc.In addition to their roles in metabolism,
both p110a and p110b are also essential
for normal mammalian growth and devel-
opment: germline deletion of either iso-
form results in embryonic lethality (Bi
et al., 2002). Jia et al. (2008) showed that
deletion of p110b in mouse embryo fibro-
blasts (MEFs) retarded cell proliferation
but had negligible effect on Akt phosphor-
ylation in response to insulin and EGF,
suggesting an Akt-independent role for
p110b in mitogenesis. Interestingly, re-
constitution of p110b-KO MEFs with a
kinase-dead p110b restored normal cell
proliferation, suggesting a kinase-inde-
pendent scaffolding function for p110b in
growth and proliferation. Previous work
has shown that p110b can serve as a sig-
naling conduit for G protein coupled re-
ceptor (GPCR)-linked PI3K signaling and
that this isoform is less important than
p110a in RTK signaling (Guillermet-
Guibert et al., 2008). A model to explain
this observation is that p110b has an
additional kinase-independent ‘‘adaptor’’
function in signaling, coupling an as-yet-
unidentified signaling molecule to GPCRs
and RTKs (Figure 1B). Furthermore,
p110b has been associated with Rab5
and clathrin-coated endocytic vesicles
(Shin et al., 2005), and phosphoinositides
regulate the endocytic pathway. Consis-
tent with these observations, Jia et al.
(2008) showed that transferrin uptake,
a surrogate marker for receptor-mediated
endocytosis, was defective in p110b KO
cells. This endocytic defect was also res-
cued by the kinase-dead p110b, suggest-
ing an analogous scaffolding function for
p110b in regulation of receptor-mediated
endocytosis. Taken together, these data
suggest that p110b likely recruits addi-
tional protein(s) important for both GPCR-
linked PI3K signaling and endocytosis, a
function that is largely independent of its
lipid kinase activity.
Alterations that lead to increased PI3K
signaling confer a survival and growth
advantage and are frequent in human
tumors. Activating point mutations and
gene amplification of the p110a isoform
have been detected in a variety of cancers
(Engelman et al., 2006). Additionally,
PTEN, a tumor suppressor that antago-
nizes PI3K activity by dephosphorylating
PIP3, is deleted or mutated in many
cancers. Since activating mutations in
p110b have not been observed in human
cancers, one might predict that p110a
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involved in producing PIP3 in oncogene-
induced tumors. Surprisingly, Jia et al.
(2008) show that p110b appears to play
a predominant role in oncogenesis. Loss
of p110b abrogated transformation of
immortalized MEFs by mutant Ras and
mutant EGFR, while loss of p110a had
a less pronounced effect. In a mouse
model of prostate cancer induced by
PTEN loss, concomitant ablation of
p110b—but not p110a—led to decreased
Akt phosphorylation in the prostate and
prevented the development of high-grade
prostatic intraepithelial neoplasia (PIN).
These findings are consistent with the
model put forth by Knight et al. (2006)
that p110b generates a basal pool of
PIP3 that defines a threshold for p110a
activation necessary for signaling. The au-
thors posit that inactivation of PTEN rai-
ses the basal PIP3 levels generated by
p110b, thereby lowering the threshold
for Akt activation and transformation.
Prior studies have shown that overex-
pression of p110b is sufficient to induce
transformation of chicken embryo fibro-
blasts (Kang et al., 2006). Loss of p110a
may fail to abrogate tumor formation due
to loss of PTEN because the basal levels
of PIP3 are sufficiently high in PTEN
/
cells for activation of Akt and for mainte-
nance of the transformed phenotype.
Notably, Jia et al. (2008) evaluated pros-
tate tumorigenesis at 12 weeks of age. It
would be interesting to assess these
mice at later time points, when prostate-
specific PTEN loss has been shown to re-
sult in more aggressive cancers (Wanget al., 2003). Perhaps over time the ab-
sence of p110b will be insufficient to
overcome the elevated basal PIP3 levels,
and the proliferative effects of unopposed
p110a signaling will drive tumor develop-
ment. In this setting, loss of both p110a
and p110b might be necessary to prevent
tumorigenesis. Alternatively, differential
signaling from unidentified upstream
GPCRs or RTKs, distinct interactions
with signaling components, or phosphor-
ylation of unique downstream effectors
could explain the differences observed
following deletion of p110a versus p110b
(Figure 1B). To further elucidate the ki-
nase-independent ‘‘scaffolding’’ function
of p110b in vivo, it would be interesting
to determine whether prostate-specific
knockin of the kinase-dead mutant p110b
fails to abrogate PTEN-induced tumori-
genesis.
In summary, Jia et al. (2008) present in-
triguing evidence for p110b as a mediator
of diverse cellular processes. They pro-
pose that, in contrast to p110a, p110b
has a kinase-dependent role in oncogenic
transformation that is distinct from its ki-
nase-independent roles in endocytosis,
cell proliferation, and potentially, glucose
homeostasis, making this isoform of
PI3K an attractive target for therapeutic
intervention that could perhaps minimize
potential side effects of global PI3K
inhibition.
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